Latest Research, Industry, Medical and Scientific News
Post-acute care nurses are right on target with continence assessment and management, a new study finds. But their patients are largely unaware of these activities and think they’re going it alone, investigators say. The researchers conducted interviews with 10 nursing staff and 10 patients in two geriatric units of a rehabilitation hospital. Perhaps not surprisingly, nurses and patients had very different experiences of incontinence care. Read more.
Source: Urology Times, November 12, 2021
It is important for clinicians to perform ambulatory blood pressure monitoring (ABPM) for patients taking new prescribed medications, as they may affect blood pressure or heart rate in detrimental ways. It is especially important to monitor patients with overactive bladder (OAB), as this group has an increasing abundance of novel medicines available to them. In a recent study presented at the 2021 American Urological Association Annual Meeting,¹ Michael A. Weber, MD, and co-authors assessed the blood pressure and heart rate profiles of the beta 3 adrenergic receptor agonist vibegron (Gemtesa) in treating patients with OAB. Read more.
Source: Urology Times, November 5 2021
Principle Business Enterprises, Inc., (PBE), which manufactures Tranquility® superabsorbent products, and the Elizabeth Dole Foundation, a prominent military Caregivers advocacy group, have partnered to provide Veterans and their families free in-home help. Their joint campaign themed “Relief and Freedom for Veteran Caregivers” encourages Caregivers of wounded, ill or injured service members to apply for free respite support and, for those with absorbent product needs, a customized incontinence care kit at TranquilityProducts.com/Respite. Read more.
Source: PRNewswire, November 1, 2021
The FDA has granted a breakthrough device designation to the leva Digital Therapeutic System for use as a first-line treatment in women with chronic fecal incontinence (FI) in women, according to Renovia, the developer of the device. The breakthrough device designation will expedite the development and regulatory review of this treatment system in female patients with FI. Benefits of the designation include priority review from the FDA for clinical trial protocols and commercialization decisions, and potentially facilitating Medicare reimbursement if the FDA approves the device. Read more.
Source: Urology Times, November 1, 2021
Automated machines quietly raise and lower trays of liquid silicone, water and a paraffin-like material in a Stewartville facility to create a new solution to an age-old medical condition that afflicts an estimated 2 percent of the world’s population. Multiple, carefully monitored dips create trays of 400 silicone inserts with a small bubble of liquid in four minutes. The inserts then move on to packaging to eventually be shipped to Minnesota Medical Technologies’ waiting customers in a growing number of countries. Designed by and created by a local team led by brothers Jim and Philip Conway, the patented myMiracle device is a small, lubricated anal insert to be used as a simple and discreet way to treat fecal incontinence. Read more.
Source: Post-Bulletin, Rochester, Minn., August 7, 2021
Researchers at the Ecole Polytechnique Fédérale de Lausanne in Switzerland developed two complementary benchtop bladder models that could help in understanding the mechanisms behind recurring urinary tract infections (UTIs). The first involves bladder organoids, which allow the researchers to study bacterial-bladder cell interactions under realistic conditions, which include the 3D multi-layered architecture of the bladder wall. The second is a bladder-on-a-chip, which includes additional features that mimic the bladder environment, including the mechanical effects of bladder filling and voiding and bladder vasculature. Read more.
Source: Medgadget, August 3, 2021